RU

Ravindra Utreshwar Ghumbre

Active Director Director DIN 09818245
DIN 09818245 First appointment Dec 2022 Primary industry Trading
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Ravindra Utreshwar Ghumbre

Data last updated:

Ravindra Utreshwar Ghumbre is a Director at John Mark Pharmaceuticals Limited (since 2022). The company operates in Trading.

DIN 09818245
Primary Designation Director
Industry Trading
First Appointment 09 Dec 2022
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
John Mark Pharmaceuticals Limited U51909PN2022PLC216794
Director09 Dec 20222022Active

Board colleagues of Ravindra Utreshwar Ghumbre

Directorship timeline

Open interactive timeline →
John Mark Pharmaceuticals Limited
Premium access

Shareholding and investment profile for Ravindra Utreshwar Ghumbre

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravindra Utreshwar Ghumbre

Ravindra Utreshwar Ghumbre currently holds 1 directorship: John Mark Pharmaceuticals Limited (Director, since 09 Dec 2022).

Ravindra Utreshwar Ghumbre was first appointed on 09 Dec 2022 as Director at John Mark Pharmaceuticals Limited.

The current boards of Ravindra Utreshwar Ghumbre's companies include Arjunsingh Jyotsingh Chavan (John Mark Pharmaceuticals Limited), Dinesh Pralhadsing Rajput (John Mark Pharmaceuticals Limited), Mayur Pramod Panjabi (John Mark Pharmaceuticals Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available